Phosphocreatine (Seldomalfa): the IV drip and injection \"for energy\" — label, human studies and anti-doping rules
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120

Phosphocreatine (Seldomalfa): the IV drip and injection \"for energy\" — label, human studies and anti-doping rules

Phosphocreatine (Seldomalfa) is registered to protect the heart during surgery: fewer arrhythmias in a pooled analysis of 26 trials. Dosing, sport and WADA rules.

Phosphocreatine (Seldomalfa): the IV drip and injection \"for energy\" — label, human studies and anti-doping rules
Phosphocreatine has been registered in Italy since 1965 for protecting the heart during surgery, and athletes have used it for decades. A review of 27 sources: how it relates to cellular energy, what human studies showed in cardiac surgery and exercise, how it is given, what WADA says and who should see a doctor first.

Key points

Phosphocreatine (creatine phosphate, sodium salt) is an Italian drug for infusion and injection, registered since 1965 [1]. The table shows where it has been studied in humans and what was found.

WhereHow it helpsWhat human studies showed
Cardiac surgerycardioprotection — the only label indication: the drug is added to the solution that stops the heart [1]pooled analysis of 26 randomised trials, 1,948 adults and children (2018): serious arrhythmias 16 % versus 28 %, inotropic support needed in 27 % versus 44 %, spontaneous return of rhythm 50 % versus 34 % [10]; valve replacement, 50 patients: spontaneous rhythm return 40 % versus 8 %, arrhythmias 8 % versus 32 % [25]
Myocardial infarctionfewer arrhythmias60 patients (1988): ventricular premature beats in 24 hours 690 versus 2,468 [13]
Coronary stentscardiac injury markers rise less often400 patients (2015): marker rise 8 % versus 19 % [14]
Viral myocarditishigher "overall efficacy"pooled analysis of 9 trials, 1,116 patients (2025): 1.22 times higher [15]
Heart failure and infarctionpossibly rhythm and breathlessnessCochrane review, 1,474 patients (2011): rhythm and breathlessness possibly better [17]
Physical workloadmore total work8 untrained men, intravenous injection versus placebo (1996): total workload +5.8 %, workload to lactate accumulation +6.8 % [7]
Strength (oral phosphocreatine with blueberry extract)greater rise in peak torque28 days, 33 men (2021): 99.9 → 119.2 N·m versus 99.95 → 112.0 on creatine, no significant gain on placebo [9]

How it helps

A fast energy reserve

Muscle and heart cells hold their own phosphocreatine as a fast energy reserve. The enzyme creatine kinase transfers one phosphate from it to ADP (the "discharged battery") and rebuilds ATP — the cell's main battery that powers contraction: phosphocreatine + ADP → creatine + ATP [1, 20]. After a 6-second sprint the muscle's phosphocreatine store is 57 % lower, and by the tenth second it is almost exhausted [21].

Two ways to charge one battery

Another Italian "energy" infusion is fructose-1,6-diphosphate (Esafosfina). Both rebuild ATP by different routes [20, 22]:

  • Phosphocreatine — one step, creatine kinase; one ATP per molecule at once; the fastest reserve; after infusion half of it leaves the blood in 5–12 minutes.
  • Fructose-1,6-diphosphate — a link in glucose breakdown after phosphofructokinase; four ATP per molecule down the chain; in a 6-second sprint glycolysis supplied about half of the ATP [21]; half leaves the blood in 10–15 minutes.

Label indications are cardioprotection in surgery and confirmed low blood phosphate [1, 22].

What happens in the blood

The time for half of the phosphocreatine to leave the blood is 0.09–0.2 h in humans (5–12 minutes). After 5 g by slow infusion, plasma levels are below 5 nmol/mL at 40 minutes [1]. In 6 children with viral myocarditis given 2 g intravenously, the half-life of phosphocreatine was 0.24 h and that of creatine 0.83 h; the area under the curve was 79.0 h·µg/mL for creatine versus 17.2 for phosphocreatine: the drug breaks down to creatine, and there is 4.6 times more creatine in the blood than the drug itself [2]. A 2021 review attributes the cardiac effect not to energy but to membrane binding and reduced platelet aggregation [3].

Cardiac surgery

Pooled analysis 2018 — 26 randomised trials, adults and children: fewer serious arrhythmias, less need for inotropic support (figures in Key points) [10].

Pooled analysis 2016 — 41 studies, including ischaemic heart disease and heart failure as well as surgery: pooled odds of death 29 % lower; crude totals 3.5 % versus 10.6 %; the headline figure is borderline [11].

Where it was used: Italy (heart failure, 13 patients, 1996) [24]; United Kingdom (valve replacement, 50 patients) [25]; Poland (bypass surgery, 40 patients) [26]; Czech Republic (infarction in the elderly, 50 patients) [27]; China (myocarditis, 2025 pooled analysis) [15].

Sport

  • Survey 2020–2021, 138 national-team track-and-field athletes (published 2026): 56.5 % received infusions; phosphocreatine was named by 60 of 93 who answered the question on composition (64.5 %) — the second most common [4].
  • 1996, 8 untrained men: intravenous injection versus placebo — higher total workload (figures in Key points) [7].
  • 1997, review, cyclists: 2–4 g a day intravenously, faster recovery [6].
  • 2021, oral phosphocreatine with blueberry extract: 28 days, 33 men — peak torque increased (comparison with creatine and placebo in Key points) [9].

Oral creatine, by the position of the International Society of Sports Nutrition (2017), reliably raises muscle creatine and improves performance in short, powerful efforts; up to 30 g a day for up to 5 years is safe in healthy people [8].

How to take it

Indication, section 4.1 — the only one, verbatim: "Cardioprotection in cardiac surgery by addition to cardioplegic solutions." A cardioplegic solution stops the heart for the duration of surgery [1].

Regimens, section 4.2: 1 g intravenously 1–2 times a day as a 30–45-minute infusion; 5 g intravenously once a day over 45–60 minutes; 500 mg deep intramuscularly 1–2 times a day; 10 mmol/L in cardioplegic solution [1].

Registered forms [1]:

FormCompositionConcentration
Intravenous infusion1 g + 50 mL solvent20 mg/mL
Intravenous infusion5 g + 50 mL solvent100 mg/mL
Intravenous infusion10 g + 100 mL solvent100 mg/mL
Intramuscular only (with local anaesthetic)500 mg + 4 mL solvent125 mg/mL

Anti-doping

Neither phosphocreatine nor creatine appears on the 2026 Prohibited List — a search returns 0 matches; section S0 (non-approved substances) does not apply because the drug is registered in Italy [18]. Method M2.2 is prohibited: "intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations" [19]. The solvent for a 1 g or 5 g vial is 50 mL: one vial fits the limit, two vials are exactly 100 mL, and any line flush exceeds it. More than 100 mL outside hospital requires a therapeutic use exemption (TUE). An injection by syringe is not prohibited if the substance is permitted and the volume stays within 100 mL per 12 hours [18].

Who should see a doctor first

Prescribing is a doctor's decision: sport and any other use are off-label. Per the label, sections 4.3–4.4 [1]:

  • Allergy to phosphocreatine is a contraindication; allergy and urticaria may occur (frequency unknown).
  • High doses, 5–10 g a day, only in selected patients and for short periods: they load calcium metabolism and its hormones, the kidneys and purine metabolism with phosphate; they are contraindicated in chronic kidney failure.
  • Blood pressure. Rapid intravenous injection of more than 1 g may lower blood pressure — so a 1 g infusion runs 30–45 minutes, 5 g — 45–60 minutes.
  • Salt restriction. Sodium: 180 mg per 1 g vial, 900 mg per 5 g vial.

In the 2023 trial, post-operative creatinine was 100 versus 99.5 µmol/L (1.13 versus 1.13 mg/dL) [12]; in myocarditis, adverse reactions were about equal, 1.07 to 1 [15]. No safety data in athletes have been published.

Bottom line

Phosphocreatine is a drug with one indication: an additive to the solution that stops the heart during surgery. Pooled small trials show fewer arrhythmias after surgery. It lasts minutes in the blood and breaks down to creatine. WADA bans not the molecule but more than 100 mL of infusions per 12 hours outside hospital. For short, powerful efforts, oral creatine is better studied. Prescribing is a doctor's decision.

References

1. Summary of product characteristics, Italian Medicines Agency (AIFA), 04.04.2026. https://api.aifa.gov.it/aifa-bdf-eif-be/1.0.0/organizzazione/4375/farmaci/020502/stampati?ts=RCP

2. Sun Z, et al. Pharmacokinetics of phosphocreatine in children with viral myocarditis. 2019. PMID 31013362.

3. Balestrino M. Role of creatine in the heart: health and disease. Nutrients. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8067763/

4. Bezuglov E, et al. Intravenous infusions in elite track-and-field athletes: anonymous survey. Front Sports Act Living. 2026. PMID 42440853.

5. Levchenko, 2005. Dissertation abstract, 110 footballers. https://uacademic.info/en/document/0405U000622

6. Clark JF. Creatine and phosphocreatine: a review of their use in exercise and sport. J Athl Train. 1997. https://pmc.ncbi.nlm.nih.gov/articles/PMC1319235/

7. Vorobiev DV, et al. Phosphocreatine and physical performance in untrained men. Eur J Appl Physiol. 1996. PMID 8971495.

8. Kreider RB, et al. ISSN position stand: creatine supplementation. J Int Soc Sports Nutr. 2017. PMID 28615996.

9. Anders JPV, et al. Oral phosphocreatine with blueberry extract: randomized trial. J Int Soc Sports Nutr. 2021. PMID 34503541.

10. Mingxing F, Landoni G, et al. Phosphocreatine in cardiac surgery: meta-analysis of 26 RCTs. J Cardiothorac Vasc Anesth. 2018. PMID 29409711.

11. Landoni G, et al. Phosphocreatine and mortality: meta-analysis of 41 studies. Interact Cardiovasc Thorac Surg. 2016. PMID 27318357.

12. Lomivorotov V, et al. Phosphocreatine in valve surgery: randomized placebo-controlled trial, NCT02757443. BMC Anesthesiol. 2023. PMID 38030971.

13. Ruda MY, et al. Phosphocreatine in acute myocardial infarction. Am Heart J. 1988. PMID 2456682.

14. Ke-Wu D, et al. Phosphocreatine after coronary stenting. Angiology. 2015. PMID 24368725.

15. Wang Y, et al. Phosphocreatine in viral myocarditis: meta-analysis of 9 trials. PLoS One. 2025. PMID 39854433.

16. Cheuk DK, et al. Creatine and its analogues for cardiotoxicity of chemotherapy in children: Cochrane review. 2016. PMID 27552363.

17. Horjus DL, et al. Creatine and creatine analogues in hypertensive and heart failure patients: Cochrane review. 2011. PMID 22071819.

18. WADA, Prohibited List. https://www.wada-ama.org/en/prohibited-list

19. WADA, 2026 Prohibited List (PDF). https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

20. Baker JS, et al. Energy systems of muscle. J Nutr Metab. 2010. PMID 21188163.

21. Gaitanos GC, et al. Human muscle metabolism during intermittent maximal exercise. J Appl Physiol. 1993. PMID 8226473.

22. Fructose-1,6-diphosphate summary of product characteristics, AIFA. https://api.aifa.gov.it/aifa-bdf-eif-be/1.0.0/organizzazione/3602/farmaci/8783/stampati?ts=RCP

23. Ehringer WD, et al. Membrane permeability to phosphocreatine, human umbilical cells in vitro. Mol Cell Biochem. 2000. PMID 10976756.

24. Ferraro S, et al. Phosphocreatine in heart failure: double-blind crossover. Clin Cardiol. 1996. PMID 8874988.

25. Chambers DJ, et al. Creatine phosphate in valve replacement. Ann Thorac Surg. 1996. PMID 8561641.

26. Cisowski M, et al. Creatine phosphate in coronary bypass surgery. J Cardiovasc Surg. 1996. PMID 10064355.

27. Weber P, et al. Phosphocreatine in elderly patients with myocardial infarction. Cas Lek Cesk. 1995. PMID 7712526.

Source: Phosphocreatine (Seldomalfa): the IV drip and injection \"for energy\" — label, human studies and anti-doping rules — universum.earth. Dr. Pereligyn.

Come back
Request a call back